Q2 EPS Forecast for Cardiol Therapeutics Reduced by Analyst

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Investment analysts at Brookline Capital Markets lowered their Q2 2026 earnings estimates for Cardiol Therapeutics in a research note issued on Tuesday, May 12th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will post earnings per share of ($0.09) for the quarter, down from their prior estimate of ($0.07). The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.28) per share. Brookline Capital Markets also issued estimates for Cardiol Therapeutics’ Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.36) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07).

Several other analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a report on Tuesday, February 10th. upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price objective on shares of Cardiol Therapeutics in a research note on Monday, April 6th. Finally, Wall Street Zen upgraded shares of Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cardiol Therapeutics has an average rating of “Hold” and a consensus target price of $8.50.

Cardiol Therapeutics Stock Performance

Shares of CRDL stock opened at $1.37 on Friday. The stock has a fifty day moving average price of $1.26 and a 200 day moving average price of $1.10. The stock has a market cap of $153.19 million, a PE ratio of -4.89 and a beta of 0.77. Cardiol Therapeutics has a 1 year low of $0.88 and a 1 year high of $1.71.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Cardiol Therapeutics by 136.2% during the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after purchasing an additional 15,255 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of Cardiol Therapeutics during the third quarter valued at approximately $249,000. Virtu Financial LLC acquired a new stake in Cardiol Therapeutics during the third quarter worth approximately $154,000. Citadel Advisors LLC grew its stake in Cardiol Therapeutics by 1,132.6% in the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock worth $496,000 after acquiring an additional 425,862 shares during the period. Finally, Susquehanna International Group LLP grew its stake in Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares during the period. 12.49% of the stock is currently owned by hedge funds and other institutional investors.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.